The Indian Patent System is known for its strict prosecution of patents in the pharmaceutical sector, ever since the product patent regime being in force since 2005. Furthermore, several opportunities are provided to third parties to challenge the patent applications and multiple pre-grant oppositions; post-grant attacks are a norm for important pharma product patents. The most recent example is that of a Pneumococcal conjugate vaccine (PCV) Prevnar, which we discuss here.

Continue reading this story by Neeti Wilson, Arpita Kulshreshtha, and Gitika Suri from Anand and Anand with no paywalls by following this link.